Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca ( (GB:AZN) ) just unveiled an announcement.
AstraZeneca reported 2025 Total Revenue of $58.7 billion, up 8% at constant exchange rates, driven by growth across oncology, cardiovascular, respiratory and rare disease franchises, with Core EPS rising 11% to $9.16 and Core operating profit up 9%. The group declared a 3% higher full-year dividend and highlighted 16 blockbuster medicines as well as 16 positive Phase 3 readouts and 43 regulatory approvals in major regions over the past year, underscoring both commercial strength and pipeline productivity.
Guidance for 2026 points to mid‑to‑high single‑digit Total Revenue growth and low double‑digit Core EPS expansion at constant exchange rates, with a forecast Core tax rate of 18–22%. Management flagged more than 100 ongoing Phase 3 trials and over 20 key readouts expected in 2026, while a recent NYSE listing is set to harmonise the company’s trading structure and potentially deepen its shareholder base.
Pipeline news included new approvals for cancer drugs Enhertu and Imfinzi, as well as rare disease and immunology therapies such as Wainua, Fasenra, Saphnelo, Koselugo and Soliris across the U.S., EU, China and Japan, along with regulatory submissions for several late‑stage assets including Datroway, baxdrostat and gefurulimab. Fourth‑quarter figures showed modest 2% revenue growth at constant exchange rates, pressure on gross margin from royalty buyout costs, and increased investment in R&D, particularly in transformative technologies like cell therapy, bispecific immuno‑oncology and antibody‑drug conjugates, signalling continued long‑term innovation spend.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development and commercialisation of prescription medicines, with core strengths in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. The company targets major markets worldwide and now has its ordinary shares trading in London, New York and Stockholm, broadening its international investor base.
For an in-depth examination of AZN stock, go to TipRanks’ Overview page.